Please assess the completion status of the following clinical trial:

Trial Title: Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be willing and able to provide fecal samples according to protocol schedule~* COHORT A~* Diagnosis of metastatic colorectal cancer, where the metastatic disease has not been previously treated~* Scheduled to begin fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or folinic acid-fluorouracil-irinotecan (FOLFIRI) based chemotherapy for the advanced disease~* Must have radiologic evidence of disease~* COHORT B~* Diagnosis of metastatic cancer~* Scheduled to begin pembrolizumab or another anti-PD-1 or anti-PD-L1 antibody as single agent therapy for the treatment of the advanced disease~* Must have physical or radiologic evidence of disease~Exclusion Criteria:~* Patients with a colostomy or any other issues that may prevent the standard methods for collection of stool are not eligible for this study~* Patients are not enrolled or a research protocol for treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (gut microbiome analysis) (Type: None): Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).